After initial screening, 117 articles were selected by excluding those not addressing the impact of ctDNA on recurrence/disease/invasive disease-free survival and overall survival, not focusing on stages I–III breast cancer, or not specific to HR+/HER2− breast cancer. Here, HR is linked to breast cancer.